Multimodality therapy for carcinoma of the Bartholin gland

L. Stewart Massad, Koen De Geest

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Objective. The aim of this study was to report the value of chemoradiation in the management of cancers of the Bartholin gland. Methods. Primary treatment consisting of 45-46 Gy teletherapy radiation to the vulva, pelvis, and groins in combination with 50 mg/m2 of cisplatin and 1000 mg/m2/day of 5-fluorouracil for 5 days during the first and fifth weeks of irradiation was delivered, followed by interstitial implant or excision. Results. Two patients were free of disease at 30 and 59 months following therapy. Both patients required myocutaneous flap closure, one after excision of tumor after radiation and one after radionecrosis at the implant site. Conclusions. Primary chemoradiation may allow continence-sparing therapy for women with primary carcinoma of the Bartholin gland.

Original languageEnglish
Pages (from-to)305-307
Number of pages3
JournalGynecologic oncology
Issue number2
StatePublished - Nov 1999


Dive into the research topics of 'Multimodality therapy for carcinoma of the Bartholin gland'. Together they form a unique fingerprint.

Cite this